Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.

AIM To examine the relationship between plasma glucagon levels and insulin sensitivity and insulin secretion in obese subjects. METHODS Suppression of plasma glucagon was examined in 275 obese Hispanic Americans with varying glucose tolerance. All subjects received 2-hour OGTT and a subset (n=90) had euglycemic hyperinsulinemic clamp. During OGTT, we quantitated suppression of plasma glucagon concentration, Matsuda Index of insulin sensitivity, and insulin secretion/insulin resistance (disposition) index. Plasma glucagon suppression was compared between quartiles of insulin sensitivity and beta-cell function. RESULTS Fasting plasma glucagon levels were similar in obese subjects with normal glucose tolerance (NGT), prediabetes, and type 2 diabetes (T2D), but the fasting glucagon/insulin ratio decreased progressively from NGT to prediabetes to T2D (9.28±0.66 vs. 6.84±0.44 vs. 5.84±0.43, P<0.001). Fasting and 2-hour plasma glucagon levels during OGTT progressively increased and correlated positively with severity of insulin resistance (both Matsuda Index and euglycemic hyperinsulinemic clamp). The fasting glucagon/insulin ratio declined with worsening insulin sensitivity and beta-cell function, and correlated with whole body insulin sensitivity (Matsuda Index, r= 0.81, P<0.001) and beta-cell function (r=0.35, P<0.001) during the fasting state. The glucagon/insulin ratio also correlated and with beta-cell function during OGTT at 60 and 120 min (r= -0.47, P<0.001; r= -0.32, P<0.001). CONCLUSION Insulin-mediated suppression of glucagon secretion in obese subjects is impaired with increasing severity of glucose intolerance and parallels the severity of insulin resistance and beta-cell dysfunction.

[1]  R. Unger.  Glucagon and diabetes mellitus. , 1972, Advances in metabolic disorders.

[2]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[3]  W. A. Müller,et al.  Studies of pancreatic alpha cell function in normal and diabetic subjects. , 1970, The Journal of clinical investigation.

[4]  M. Hanefeld,et al.  Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  J. Holst,et al.  Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals , 2014, Diabetologia.

[6]  G. Shulman,et al.  Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. , 2011, American journal of physiology. Endocrinology and metabolism.

[7]  L. Orci,et al.  The alpha cell response to glucose change during perfusion of anti-insulin serum in pancreas isolated from normal rats , 1985, Diabetologia.

[8]  R. Rizza,et al.  Impact of lack of suppression of glucagon on glucose tolerance in humans. , 1999, American journal of physiology. Endocrinology and metabolism.

[9]  L. Groop,et al.  Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance , 2016, Diabetes.

[10]  R. DeFronzo,et al.  Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus , 2016, Acta Diabetologica.

[11]  B. Ahrén,et al.  Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. , 2000, Diabetes care.

[12]  R. DeFronzo,et al.  Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons , 2009, Proceedings of the National Academy of Sciences.

[13]  T. Hansen,et al.  Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids , 2018, Diabetologia.

[14]  J. Gerich,et al.  Effects of alternations of plasma free fatty acid levels on pancreatic glucagon secretion in man. , 1974, The Journal of clinical investigation.

[15]  M. Matsuda,et al.  Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.

[16]  S. Klein,et al.  Fasting-Induced Changes in Glucagon Secretion Are Dysregulated in Obesity , 2018, Diabetes.

[17]  J. Holst,et al.  Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis , 2020, Diabetes.

[18]  R. DeFronzo.  Insulin secretion, insulin resistance, and obesity. , 1982, International journal of obesity.

[19]  T. Hansen,et al.  Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation , 2016, Diabetes.

[20]  B. Ahrén,et al.  Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women , 2000, Diabetologia.

[21]  J. McDonald,et al.  Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice , 2018, Cell reports.

[22]  R. DeFronzo,et al.  The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  A. Golay,et al.  Association of fasting glucagon and proinsulin concentrations with insulin resistance , 2007, Diabetologia.

[24]  A. Golay,et al.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.

[25]  J. Holst,et al.  Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity , 2012, Diabetes, obesity & metabolism.

[26]  Catherine B. Chan,et al.  Glucose-regulated Glucagon Secretion Requires Insulin Receptor Expression in Pancreatic α-Cells* , 2005, Journal of Biological Chemistry.

[27]  R. Unger.  GLUCAGON IN PATHOGENESIS OF DIABETES , 1975, The Lancet.

[28]  G. Reaven,et al.  Quantification of Insulin Secretion and In Vivo Insulin Action in Nonobese and Moderately Obese Individuals with Normal Glucose Tolerance , 1983, Diabetes.

[29]  S. Klein,et al.  Obesity dysregulates fasting-induced changes in glucagon secretion. , 2019, The Journal of endocrinology.

[30]  G. Dimitriadis,et al.  Abnormal Glucose Modulation of Islet A- and B-Cell Responses to Arginine in Non-insulin-dependent Diabetes Mellitus , 1985, Diabetes.

[31]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[32]  K. Polonsky,et al.  Insulin signaling in alpha cells modulates glucagon secretion in vivo. , 2009, Cell metabolism.

[33]  A. Cherrington,et al.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.

[34]  Bei B. Zhang,et al.  Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.

[35]  R. DeFronzo,et al.  Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. , 2019, The Journal of clinical endocrinology and metabolism.

[36]  L. Velloso,et al.  Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas) , 2015, Diabetologia.

[37]  R. Duggirala,et al.  Genome-Wide Linkage Scan for Genes Influencing Plasma Triglyceride Levels in the Veterans Administration Genetic Epidemiology Study , 2009, Diabetes.

[38]  P. Savage,et al.  Arginine is preferred to glucagon for stimulation testing of β-cell function. , 2014, American journal of physiology. Endocrinology and metabolism.

[39]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[40]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.

[41]  R. Unger,et al.  Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Ashcroft,et al.  Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes , 2013, Cell metabolism.

[43]  D. Smith,et al.  Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion , 2017, Scientific Reports.

[44]  A. Baron,et al.  Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.

[45]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[46]  J. Dekker,et al.  A prospective study on glucagon responses to oral glucose and mixed meal and 7‐year change in fasting glucose , 2019, Clinical endocrinology.

[47]  J. Holst,et al.  Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. , 2010, Metabolism: clinical and experimental.